Fairmount Funds Management LLC insider trades
Open-market stock purchases and sales by Fairmount Funds Management LLC, Director at Spyre Therapeutics, Inc, from SEC Form 4 filings since Jul 6, 2020.
Track record: 46% of 13 scored buys are up 5% or more since purchase, averaging +45%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Jun 23, 2026 | SYRE Spyre Therapeutics, Inc | Bought (not open market) | — |
| Jun 23, 2026 | SYRE Spyre Therapeutics, Inc | Sold | $400M |
| Jun 23, 2026 | SYRE Spyre Therapeutics, Inc | Bought (not open market) | — |
| Jun 9, 2026 | APGE Apogee Therapeutics, Inc | Bought (not open market) | — |
| Jun 9, 2026 | JBIO Jade Biosciences, Inc | Bought (not open market) | — |
| Jun 2, 2026 | CBIO Crescent Biopharma, Inc | Bought (not open market) | — |
| Jun 2, 2026 | ORKA Oruka Therapeutics, Inc | Bought (not open market) | — |
| May 27, 2026 | SYRE Spyre Therapeutics, Inc | Bought (not open market) | — |
| May 11, 2026 | VRDN Viridian Therapeutics, Inc.\DE | Bought | $20M |
| Mar 31, 2026 | COGT Cogent Biosciences, Inc | Bought (not open market) | — |
| Mar 31, 2026 | COGT Cogent Biosciences, Inc | Sold | $243M |
| Mar 31, 2026 | COGT Cogent Biosciences, Inc | Bought (not open market) | — |
| Mar 31, 2026 | ZBIO Zenas BioPharma, Inc | Bought | $3M |
| Mar 23, 2026 | DMRA Damora Therapeutics, Inc | Bought (not open market) | — |
| Feb 9, 2026 | GLTO Galecto, Inc | Bought (not open market) | — |
| Feb 9, 2026 | GLTO Galecto, Inc | Bought (not open market) | — |
| Feb 9, 2026 | GLTO Galecto, Inc | Bought (not open market) | — |
| Feb 9, 2026 | GLTO Galecto, Inc | Bought (not open market) | — |
| Jan 22, 2026 | APGE Apogee Therapeutics, Inc | Sold | $134M |
| Jan 22, 2026 | COGT Cogent Biosciences, Inc | Sold | $127M |
| Dec 4, 2025 | CBIO Crescent Biopharma, Inc | Bought | $18.2M |
| Dec 4, 2025 | CBIO Crescent Biopharma, Inc | Bought | $1.8M |
| Oct 23, 2025 | VRDN Viridian Therapeutics, Inc.\DE | Bought | $10M |
| Oct 7, 2025 | ZBIO Zenas BioPharma, Inc | Bought | $6M |
| Oct 6, 2025 | JBIO Jade Biosciences, Inc | Bought (not open market) | $12.2M |
Companies traded
- SYRE Spyre Therapeutics, Inc: 1 sale, last Jun 23, 2026
- APGE Apogee Therapeutics, Inc: 3 buys, 1 sale, last Jun 9, 2026
- JBIO Jade Biosciences, Inc: other filings, last Jun 9, 2026
- CBIO Crescent Biopharma, Inc: 2 buys, last Jun 2, 2026
- ORKA Oruka Therapeutics, Inc: other filings, last Jun 2, 2026
- VRDN Viridian Therapeutics, Inc.\DE: 6 buys, last May 11, 2026
- COGT Cogent Biosciences, Inc: 3 buys, 2 sales, last Mar 31, 2026
- ZBIO Zenas BioPharma, Inc: 4 buys, last Mar 31, 2026
- DMRA Damora Therapeutics, Inc: other filings, last Mar 23, 2026
- GLTO Galecto, Inc: other filings, last Feb 9, 2026
- DNTH Dianthus Therapeutics, Inc /DE/: 5 buys, last Sep 27, 2024
- AGLE Spyre Therapeutics, Inc: other filings, last Nov 24, 2023
Get free alerts when Fairmount Funds Management LLC files a new trade →